Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Genetic mutations in dystrophin manifest in Duchenne muscular dystrophy (DMD), the most commonly inherited muscle disease. Here, we report on reprogramming of fibroblasts from two DMD mouse models into induced myogenic progenitor cells (iMPCs) by MyoD overexpression in concert with small molecule treatment. DMD iMPCs proliferate extensively, while expressing myogenic stem cell markers including Pax7 and Myf5. Additionally, DMD iMPCs readily give rise to multinucleated myofibers that express mature skeletal muscle markers; however, they lack DYSTROPHIN expression. Utilizing an exon skipping-based approach with CRISPR/Cas9, we report on genetic correction of the dystrophin mutation in DMD iMPCs and restoration of protein expression in vitro. Furthermore, engraftment of corrected DMD iMPCs into the muscles of dystrophic mice restored DYSTROPHIN expression and contributed to the muscle stem cell reservoir. Collectively, our findings report on a novel in vitro cellular model for DMD and utilize it in conjunction with gene editing to restore DYSTROPHIN expression in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828535 | PMC |
| http://dx.doi.org/10.1016/j.stemcr.2021.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurological impairments in Duchenne muscular dystrophy: A comprehensive review.
Acta Neurol Belg
September 2025
Department of Pediatric Orthopedics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Section 1, Riyue Avenue, Qingyang District, Chengdu, Sichuan Province, China.
Duchenne muscular dystrophy, the most prevalent form of muscular dystrophy, is characterized by neurological complications including cognitive impairment, neuropsychiatric disorders, and epilepsy. Neuroimaging investigations have demonstrated structural brain alterations, hemodynamic disturbances, and metabolic dysregulation in individuals with Duchenne muscular dystrophy. These neurological impairments are primarily attributed to cerebral dystrophin deficiency and subsequent downstream molecular/cellular abnormalities, including altered excitation-inhibition balance, blood-brain barrier disruption, calcium dysregulation, and neuroinflammation.
View Article and Find Full Text PDFAssessment of skeletal muscle deformability during clinical paralysis in EAE, a mouse model of multiple sclerosis.
Micron
August 2025
Department of Biophysical Microstructures, Institute of Nuclear Physics, Polish Academy of Sciences, Krakow PL-31342, Poland.
Multiple sclerosis (MS) and its mouse model, experimental autoimmune encephalomyelitis (EAE), are neurodegenerative diseases associated with inflammation and demyelination of the central nervous system, often leading to severe motor deficits, including progressive paralysis and spasticity. Although the neurological aspects of MS and EAE are widely described, the influence of disease progression on skeletal muscle structure and mechanics remains a largely unexplored field. In the present study, we assessed skeletal muscle deformability during EAE-induced paralysis using atomic force microscopy (AFM), histological examination, and analysis of dystrophin and laminin expression in relation to EAE disease severity.
View Article and Find Full Text PDFDual S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathy.
bioRxiv
August 2025
Department of Pharmacology & Therapeutics and Myology Institute, University of Florida College of Medicine; Gainesville, FL USA.
Duchenne muscular dystrophy (DMD) is a lethal pediatric striated muscle disease caused by loss of dystrophin for which there is no cure. Cardiomyopathy is the leading cause of death amongst individuals with DMD, and effective therapeutics to treat DMD cardiomyopathy are a major unmet clinical need. This work investigated adeno-associated viral (AAV) gene therapy approaches to treat DMD cardiomyopathy by overexpression of the calcium binding proteins S100A1 and apoptosis repressor with caspase recruitment domains (ARC).
View Article and Find Full Text PDFEngineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives.
Biomedicines
August 2025
Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, NHC Key Laboratory of Chronobiology, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Skeletal muscle, constituting ~40% of body mass, serves as a primary effector for movement and a key metabolic regulator through myokine secretion. Hereditary myopathies, including dystrophinopathies (DMD/BMD), limb-girdle muscular dystrophies (LGMD), and metabolic disorders like Pompe disease, arise from pathogenic mutations in structural, metabolic, or ion channel genes, leading to progressive weakness and multi-organ dysfunction. Gene therapy has emerged as a transformative strategy, leveraging viral and non-viral vectors to deliver therapeutic nucleic acids.
View Article and Find Full Text PDFGene therapy for Duchenne muscular dystrophy.
Brain Dev
August 2025
Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.. Electronic address:
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder caused by variants of the DMD that leads to progressive muscle degeneration. Recent advances in gene therapy have opened new therapeutic avenues, particularly through the use of adeno-associated virus (AAV)-mediated micro-dystrophin delivery. Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, has demonstrated transgene expression and potential functional improvement in early phase trials, although its long-term efficacy, durability, and safety remain unconfirmed.
View Article and Find Full Text PDF